Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...


This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
CVRx, Inc. Identifier:
First received: August 31, 2012
Last updated: January 18, 2017
Last verified: January 2017

The BAROSTIM NEO HTN trial is a prospective, randomized, controlled trial to demonstrate the safety and efficacy of the Barostim Neo system in subjects with resistant hypertension.

Currently, the BAROSTIM NEO HTN trial is not actively enrolling. CVRx is conducting long-term follow-up of patients implanted with the BAROSTIM NEO device. This update was not done for any subject protection concerns that would preclude continuation of the investigation.

Condition Intervention
Uncontrolled Hypertension
Device: Neo Baroreflex Activation Therapy System
Other: Standard of care medical management only

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Masking Description:
Open Label
Primary Purpose: Treatment
Official Title: CVRx BAROSTIM NEO Hypertension Pivotal Trial

Further study details as provided by CVRx, Inc.:

Primary Outcome Measures:
  • Primary Safety Objective [ Time Frame: 30 days ]
    To demonstrate the safety of the Neo system by reporting all adverse events that are complications between implant and 30 days post-implant in the device arm. The incidence of adverse events will be categorized by relatedness.

  • Primary Efficacy Objective [ Time Frame: 6 months ]
    To demonstrate a significant reduction between the two treatment arms of protocol defined automated office cuff systolic blood pressure (SBP) from baseline to 6 months post-activation.

Secondary Outcome Measures:
  • Secondary Efficacy Objective 1 [ Time Frame: 12 months ]
    To demonstrate a significant reduction within the device arm of office cuff systolic blood pressure (SBP) between baseline and 12 months post-activation.

  • Secondary Efficacy Objective 2 [ Time Frame: 12 months ]
    To demonstrate a significant reduction within the device arm of 24-hour ambulatory systolic blood pressure (SBP) between baseline and 12 months post-activation.

  • Secondary Safety Objective [ Time Frame: 6 months ]
    To demonstrate the safety of the Neo system by reporting all hypertensive emergencies from activation to 6 months post activation. The incidence of hypertensive emergencies will be categorized by study arm.

Estimated Enrollment: 310
Study Start Date: January 2013
Estimated Study Completion Date: September 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Neo Baroreflex Activation Therapy System
Patients are randomized to receive Neo Baroreflex Activation Therapy System device plus optimal medical management.
Device: Neo Baroreflex Activation Therapy System
Other Names:
  • Neo System
  • Barostim Neo System
Active Comparator: Medical Management Arm
Patients are randomized to receive optimal medical management alone.
Other: Standard of care medical management only
Patients will continue with medical therapy for standard of care of their hypertension.


Ages Eligible for Study:   21 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria Highlights:

  • Age at least 21 years and no more than 80 years at the time of randomization.
  • On four or more maximally tolerated anti-hypertensive medications, one of which is a diuretic. The antihypertensive medication regimen must remain unchanged for 4 weeks prior to screening and must be expected to remain unchanged for at least 6 months during follow-up.
  • Protocol defined systolic blood pressure greater than or equal to 160 mmHg.
  • Protocol defined 24-hour Ambulatory Blood Pressure Monitoring (ABPM) greater than or equal to 135 mmHg.
  • Serum estimated glomerular filtration rate (eGFR) > 29 mL/min/1.73 m^2.
  • Appropriate surgical candidate.
  • Women of childbearing potential must use a medically accepted method of birth control and agree to continue use of this method for the duration of the study. Women of childbearing potential must have a negative pregnancy test within 14 days prior to randomization.

Exclusion Criteria Highlights:

  • Known or suspected baroreflex failure or autonomic neuropathy.
  • Myocardial infarction, hypertensive crisis, symptomatic orthostatic hypotension, unstable angina, syncope, or cerebral vascular accident within the 3 months.
  • Hypertension secondary to an identifiable and treatable cause other than sleep apnea.
  • Prior surgery, radiation, or endovascular stent placement in the carotid sinus region.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01679132

United States, Arizona
Arizona Heart Rhythm Research Center
Phoenix, Arizona, United States, 85006
United States, California
University of Southern California
Los Angeles, California, United States, 90033
United States, District of Columbia
George Washington University
Washington, District of Columbia, United States, 20037
United States, Florida
Florida Hospital
Orlando, Florida, United States, 32803
Tampa General Hospital
Tampa, Florida, United States, 33606
United States, Louisiana
Cardiovascular Institute of the South
Houma, Louisiana, United States, 70360
United States, Michigan
Cardiac and Vascular Research Center of Northern Michigan
Petosky, Michigan, United States, 49770
Michigan CardioVascular Institute
Saginaw, Michigan, United States, 48601
United States, Nevada
University Medical Center of Southern Nevada
Las Vegas, Nevada, United States, 89102
United States, Oklahoma
Oklahoma Heart hospital
Oklahoma City, Oklahoma, United States, 73120
United States, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
United States, Wisconsin
Aspirus Wausau Hospital
Wausau, Wisconsin, United States, 54401
Sponsors and Collaborators
CVRx, Inc.
Study Chair: George Bakris, MD The University of Chicago Medicine
Study Chair: John Bisognano, MD University of Rochester
Study Chair: Fred Weaver, MD Keck School of Medicine of the University of Southern California
Study Chair: William Abraham, MD Ohio State University
  More Information

Responsible Party: CVRx, Inc. Identifier: NCT01679132     History of Changes
Other Study ID Numbers: 360039
Study First Received: August 31, 2012
Last Updated: January 18, 2017

Keywords provided by CVRx, Inc.:
High Blood Pressure
Blood Pressure
Cardiovascular Disease
Resistant Hypertension

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases processed this record on May 25, 2017